Geron News

Geron Corporation today announced two presentations of its anti-cancer drug, GRN163L, given at the American Society of Clinical Oncology annual meeting in Chicago.

David Greenwood - EVP, CFO Tom Okarma - CEO Analysts Glen Gechlik- Needham & Co.

Bush FDA wing-nut god appointee denies spinal cord INJURY REPAIR trial for the second time, even though the company met all of the bush fda requirements, both times::: A legacy that history should rightly call ...

Geron Corporation has released a series of press releases over several years stating that "next year" it would start the first human trials using ES cells.

“New and innovative media products will supplement the tools currently available to scientists in this rapidly evolving field”

VANCOUVER & MENLO PARK, Calif. - STEMCELL Technologies, Inc. and Geron Corporation today announced that Geron has granted a license to STEMCELL Technologies under Geron intellectual property relating to primate ... via Centre Daily Times

It is huge medical news that you won't read about in the press, and it illustrates the power of Geron's first in man telomerase inhibitor. via Toledo Talk

“The government has made a major investment in creating the Centre and this grant will allow us to progress toward our goal of delivering new treatments for debilitating diseases.”

Geron Corporation announced today two grant awards to the University of Edinburgh from the UK Stem Cell Foundation, with funding from the Medical Research Council and Scottish Enterprise. via Medical News

MENLO PARK, Calif. - Geron Corporation will announce its financial results for the 2008 first quarter on Tuesday, April 29, 2008, after the closing of the equity market. via Earth Times

Sign-up Now for a Free Test Drive of a New Sales Prospecting and Leads subscription services. via The San Francisco Business Times

“These Geron presentations and the many others on telomerase and cancer continue to highlight the importance of telomerase-targeted therapeutics for the treatment of cancer”

Apr 16, 2008 - Geron Corporation today announced five presentations of its anti-cancer drug, GRN163L, given at this year's American Association for Cancer Research Annual Meeting in San Diego, CA. via Med Ad News

Exeter Life Sciences Inc. paid Geron Corp. $1.5 million as a milestone payment. The two companies started a joint venture two years ago around cloned animal research and technology. via The San Francisco Business Times

Geron Corporation announced that is has received a milestone payment of $1.5 million from Exeter Life Sciences, Inc. via Business Wire

CV Therapeutics, Inc. , Geron Corp. and ANADIGICS, Inc. are among the most actively traded companies in Friday's pre-market trading among those with market capitalizations under $750 million. via All Stories

“We are pleased that the Patent Office has reconfirmed the validity of all three of the patents”

Mar 11, 2008 - Geron Corporation announced today that the U.S. Patent Office has upheld the validity of two additional patents for human embryonic stem cells that were challenged through reexamination ... via Med Ad News

“All these companies are Geron wannabes. . . . We are the pioneers of this and we will reap all of the fruits of that pioneering work.”

After 13 years of research costing more than $150 million, Geron says it is finally ready to conduct an unprecedented test in people with a treatment made from one of the most controversial substances in ... via SiliconValley.com

Feb 8, 2008 - Geron Corporation today announced that Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer, will present an update of the company's product development programs at 11 a.m. ... via Med Ad News

“Geron is in a strong leadership position in the development of hESC therapeutics, and we are pleased to be able to add this patent to the intellectual property portfolio that we are building to protect our investment in the field”

The production of endoderm cells is a critical step in generating pancreatic islet cells from hESCs, which Geron is developing for potential use in treating diabetes. via PR-inside.com

Geron Corporation today announced that President and Chief Executive Officer Thomas B. Okarma, Ph.D., M.D., has resumed his operational leadership of the company ' s oncology drug development activities. via Business Wire

“The agreement represents an outstanding opportunity not only for Sienna, but globally for patients, payers and clinicians who seek better, faster methods for the diagnosis and monitoring of cancer.”

Telomerase has great potential as a cancer biomarker, being present in about 95% of all epithelial cancers. via PR-inside.com

Geron Corp. said Wednesday it received a $4 million milestone payment that was triggered by an investigational new drug application for a cancer vaccine filed by Merck & Co. via San Jose Business Journal